Oppenheimer Maintains Outperform on Olema Pharmaceuticals, Raises Price Target to $48

Benzinga · 2d ago
Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and raises the price target from $45 to $48.